13Few series of adult patients with primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma (ALCL) are reported in the literature; most of them have been treated with combination chemotherapy (CHT), with only an occasional patient being autotransplanted, mainly after relapsing. The remission rate ranges from 60% to 90%, but relapses are frequent (up to 60%) and precocious (mainly in the first 24 months). The aim of our study was to analyze the outcome of a series of adult patients affected by primary systemic ALCL that were treated at our institution with a sequential intensive therapeutic program including CHT, radiotherapy (RT), and autologous bone marrow transplantation (ABMT). Sixteen consecutive, unselected patients with A...
Anaplastic large cell lymphoma (ALCL) is a common subtype of the heterogeneous group of peripheral T...
Purpose: During the last few years, the application of CD30 monoclonal antibodies has led to the ide...
BACKGROUND: Long-term outcomes of adults with first-relapsed/refractory (R/R) systemic anaplastic la...
11nonenoneFANIN, Renato; Silvestri F; Geromin A; Cerno M; Infanti L; ZAJA, Francesco; Barillari G; S...
11nonenoneFANIN, Renato; Sperotto A; Silvestri F; Cerno M; Geromin A; Stocchi R; Infanti L; PATRIARC...
Background and Objective. Although in recent years anaplastic large-cell lymphoma (ALCL) has emerged...
Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD...
Primary cutaneous CD30+ lymphoproliferative disorders include primary cutaneous anaplastic large cel...
Sixty-nine anaplastic large cell lymphomas (ALCLs) were selected from an Italian comparative trial o...
Anaplastic, CD30+, large-cell lymphoma is now a well-recognized pathologic entity that accounts for ...
Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classifie...
Twenty consecutive patients with poor-risk aggressive lym-phoma who at presentation either had eleva...
Anaplastic large cell lymphoma (ALCL) is rare hematological malignancy and subtype of mature T-cell ...
Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-positive (ALK+ ALCL) is an a...
Systemic anaplastic large cell lymphoma (ALCL) is a rare, aggressive CD30-positive non-Hodgkin lymph...
Anaplastic large cell lymphoma (ALCL) is a common subtype of the heterogeneous group of peripheral T...
Purpose: During the last few years, the application of CD30 monoclonal antibodies has led to the ide...
BACKGROUND: Long-term outcomes of adults with first-relapsed/refractory (R/R) systemic anaplastic la...
11nonenoneFANIN, Renato; Silvestri F; Geromin A; Cerno M; Infanti L; ZAJA, Francesco; Barillari G; S...
11nonenoneFANIN, Renato; Sperotto A; Silvestri F; Cerno M; Geromin A; Stocchi R; Infanti L; PATRIARC...
Background and Objective. Although in recent years anaplastic large-cell lymphoma (ALCL) has emerged...
Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD...
Primary cutaneous CD30+ lymphoproliferative disorders include primary cutaneous anaplastic large cel...
Sixty-nine anaplastic large cell lymphomas (ALCLs) were selected from an Italian comparative trial o...
Anaplastic, CD30+, large-cell lymphoma is now a well-recognized pathologic entity that accounts for ...
Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classifie...
Twenty consecutive patients with poor-risk aggressive lym-phoma who at presentation either had eleva...
Anaplastic large cell lymphoma (ALCL) is rare hematological malignancy and subtype of mature T-cell ...
Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-positive (ALK+ ALCL) is an a...
Systemic anaplastic large cell lymphoma (ALCL) is a rare, aggressive CD30-positive non-Hodgkin lymph...
Anaplastic large cell lymphoma (ALCL) is a common subtype of the heterogeneous group of peripheral T...
Purpose: During the last few years, the application of CD30 monoclonal antibodies has led to the ide...
BACKGROUND: Long-term outcomes of adults with first-relapsed/refractory (R/R) systemic anaplastic la...